Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14563
Abstract: Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years… read more here.
Keywords: haemophilia inhibitors; eptacog beta; control bleeding; treatment control ... See more keywords
Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.3.3381593
Abstract: Hemophilia A and B are X-linked hereditary bleeding disorders due to factor VIII (FVIII) or factor IX (FIX) deficiency, respectively. Major advancements have been made in the care of patients with hemophilia, yet the development… read more here.
Keywords: factor viia; recombinant factor; eptacog beta; hemophilia ... See more keywords